

Telisotuzumab vedotin (ADC)

Summary

Catalog No.	DHC34299
Alternative Names	ABBV-399
Clone ID	Telisotuzumab vedotin
Species reactivity	Human
Form	Liquid
Concentration	1 mg/ml
Purity	>90% as determined by SEC.
Clonality	Monoclonal
Applications	Research Grade Biosimilar
Target	cMet
Purification	Purified by Ion Exchange Chromatography.
Endotoxin level	Please contact with the lab for this information.
Stability and Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Note	For research use only. Not suitable for clinical or therapeutic use.

Description

Telisotuzumab vedotin is an ADC consisting of a cMET-directed antibody and Monomethyl auristatin E (MMAE) that has recently obtained the breakthrough therapy designation (BTD) for the treatment of

Recombinant Proteins & Antibodies

patients with c-Met overexpression, advanced/metastatic wild-type (WT) epithelial growth factor receptor (EGFR) non-squamous non-small cell lung cancer (sqNSCLC) that progressed during or after platinum-based chemotherapy.

Data Image
